The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Looking towards a cure in CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the concept of a cure in chronic lymphocytic leukemia (CLL) and notes that while current therapies outside of allogeneic stem cell transplantation are not curative, he is optimistic that combining novel treatments may lead to a cure for a subset of patients. Dr Davids highlights that the goal of cure is more relevant for young, fit patients with high-genetic-risk disease, whereas for older patients with low-risk genetics, controlling the disease and extending life with good quality of life is a more reasonable objective. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
